| Abstract | The calcium antagonist amlodipine may have the potential for expanded use in children owing to its physiochemistry and pharmacokinetic profile that facilitates once-daily dosing in a liquid formulation. Its safety and efficacy have not been previously evaluated in children. A retrospective analysis of 15 pediatric bone marrow transplant patients who had amlodipine incorporated into their antihypertensive drug regimen reveals significantly lower blood pressure as compared with baseline therapy (123.5+/-2.1 mmHg and 117.2+/-2.2 mmHg, systolic blood pressure before and during amlodipine, P<0.05; 81.5+/-1.8 mmHg and 75.5+/-2.6 mmHg, diastolic blood pressure before and during amlodipine, P<0.05). Amlodipine provided improved blood pressure control in this cohort and may provide a valuable pharmacologic alternative for treatment of pediatric hypertension. |
| Authors | S Khattak, J W Rogan, E F Saunders, J G Theis, G S Arbus, G Koren
(Affiliation: Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, The University of Toronto, Ontario, Canada.)
|
| Journal | Clinical pediatrics
(Clin Pediatr (Phila))
Vol. 37
Issue 1
Pg. 31-5
(Jan 1998)
ISSN: 0009-9228 UNITED STATES |
| PMID | 9475697
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
| Chemical References |
|
| Topics |
- Adolescent
- Age Factors
- Amlodipine
(administration & dosage, pharmacokinetics)
- Bone Marrow Transplantation
- Child
- Child, Preschool
- Cohort Studies
- Female
- Humans
- Hypertension
(drug therapy)
- Infant
- Kidney
(drug effects)
- Male
- Postoperative Care
|
